Melanoma (Issue 3) | Special Reports

Inducing an Immune Response With a Patient’s Tumor

September 18, 2014

Clinical Articles

Lawrence Fong, MD, discusses the systemic antitumor effect and clinical response in a phase II trial of intratumoral electroporation of plasmid interleukin-12 (IL-12) in patients with advanced melanoma.

Challenges Apparent With Current Targeted Therapies for BRAF Metastatic Melanoma

September 18, 2014

Clinical Articles

Several advances in the treatment of metastatic melanoma have occurred in the last 5 years, one of which has been the approval by the FDA of targeted treatments for patients with melanomas harboring a BRAF mutation.

Approvals Open Up New Potential Checkpoint Strategies in Metastatic Melanoma

September 13, 2014

Clinical Articles

Since the FDA approval of ipilimumab, there has been considerable interest in the potential for other immune system checkpoints, such as PD-L1 and its receptor, PD-1, to serve as therapeutic targets in metastatic melanoma.